Hypertrophic osteoarthropathy as a clinical manifestation of lung cancer

Hypertrophic Pulmonary Osteoarthropathy - An Overlooked Clue of Lung Cancer

Hypertrophic osteoarthropathy (HOA) is a syndrome that presents with classic findings of digital clubbing, arthralgia, and periostosis of tubular bones. When HOA is associated with pulmonary pathologies such as lung malignancies, it is referred to as hypertrophic pulmonary osteoarthropathy (HPOA). We present a case of an elderly woman who presents with significant pain in both hands and was eventually diagnosed with lung malignancy. This case is of interest to hospital-based internists to ensure timely diagnosis of HPOA so a brief overview of the presentation, laboratory findings, and treatment of HPOA is discussed.

Paraneoplastic syndrome of arthropathies as presenting sign for non-small cell lung cancer

The aim of this study is to showcase an example of paraneoplastic syndrome, so other healthcare providers can be aware of early NSCLC manifestations. This is also important so providers do not dismiss review of symptoms that may not seem pertinent.

Paraneoplastic syndromes in lung cancer and their management

Paraneoplastic syndromes are most frequently associated with lung cancer. This review considers a variety of paraneoplastic syndromes associated with lung cancer and discusses their pathophysiology, clinical features and management options.

Paraneoplastic syndromes associated with lung cancer

Paraneoplastic syndromes are signs or symptoms that occur as a result of organ or tissue damage at locations remote from the site of the primary tumor or metastases. Paraneoplastic syndromes associated with lung cancer can impair various organ functions and include neurologic, endocrine, dermatologic, rheumatologic, hematologic, and ophthalmological syndromes, as well as glomerulopathy and coagulopathy (Trousseau’s syndrome). The histological type of lung cancer is generally dependent on the associated syndrome, the two most common of which are humoral hypercalcemia of malignancy in squamous cell carcinoma and the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. The symptoms often precede the diagnosis of the associated lung cancer, especially when the symptoms are neurologic or dermatologic. The proposed mechanisms of paraneoplastic processes include the aberrant release of humoral mediators, such as hormones and hormone-like peptides, cytokines, and antibodies. Treating the underlying cancer is generally the most effective therapy for paraneoplastic syndromes, and treatment soon after symptom onset appears to offer the best potential for symptom improvement. In this article, we review the diagnosis, potential mechanisms, and treatments of a wide variety of paraneoplastic syndromes associated with lung cancer.